Johan E. Wallin
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Defining the underlying pathology of corticobasal syndrome using clinical features and biomarkers.
Journal: Brain : a journal of neurology
Published: December 15, 2025
Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: October 18, 2024
Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [11C]PBR28 PET.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: October 16, 2024
[11 C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome.
Journal: Synapse (New York, N.Y.)
Published: December 28, 2022
β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.
Journal: Annals of neurology
Published: May 29, 2022
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.
Journal: International journal of molecular sciences
Published: April 23, 2021
Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
Journal: Therapeutic drug monitoring
Published: November 23, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026